(Photo Credit - Nick Youngson)
ABcann Global Corporation (TSXV:ABCN) (OTC:ABCCF) announced this morning the appointment of Barry Fishman as Chief Executive Officer of the company, effective October 1, 2017. Fishman is bringing nearly 20 years of experience as a business leader in both the pharmaceutical and cannabis industries, which stands to benefit ABcann tremendously. Fishman will be replacing Aaron Keay, the current CEO and Director of ABcann.
Pharmaceutical Industry Experience
Most recently, Fishman served as CEO of international specialty pharmaceutical company Merus Labs (TSX:MSL) (NASDAQ:MSLI), culminating in the acquisition of Merus by Norgine B.V. in July, 2017 for approximately $342 million.
Related: Trading Stocks on Ally Invest
Prior to this position, Fishman previously served as CEO of both Teva Canada and Taro Canada, and is a past Chair of the Canadian Generic Manufacturers Association. He began his pharmaceutical career at Eli Lilly (NYSE:LLY), where he advanced through several cross-functional leadership roles, including Vice President of Marketing.
Cannabis Industry Experience
Besides Fishman's experience in the pharmaceutical space, He also is currently serving as a director of Aurora Cannabis Inc. (TSX:ACB) (OTC:ACBFF), as well as previously serving on the Board of Directors of Canopy Growth Corporation (TSX:WEED) (OTC:TWMJF) and Bedrocan Cannabis Corp.
Related: Bedrocan Completes Export to Brazil
"Barry's proven experience as a CEO of complex, highly-regulated organizations with international operations will serve ABcann and our shareholders well as we continue to execute our growth strategy, including the significant expansion of our production capacity, and establishing our unique leadership position in the cannabis industry," stated Ken Clement, Executive Chairman.
In connection with Mr. Fishman's appointment, the company has granted Mr. Fishman 1,250,000 stock options, each of which is exercisable into one common share for five years at a price of $0.83 per share, being the closing price of the Company's common shares on the TSXV on September 6, 2017, and vesting monthly over 36 months from the date of grant; and also agreed to issue Mr. Fishman 1,175,000 common shares, as a signing bonus, which will vest in six equal installments every six months, commencing on October 1, 2017.
Be sure to subscribe to one or more of our free e-mail newsletters so you never miss an important marijuana stock update. Our Canadian L.P. Updates newsletter focuses on Canadian Licensed Producers like ABcann. Our Canadian Updates newsletter provides a broader coverage of Canadian companies. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, and Instagram.